Literature DB >> 10998770

Workers' compensation claims from latex glove use: a longitudinal analysis of Minnesota data from 1988 to 1997.

I B Horwitz1, R D Arvey.   

Abstract

Allergic reaction experienced by health care workers from latex glove use has increasingly become the focus of researchers evaluating occupational sources of injury in health care settings. Many studies have attempted to estimate the prevalence of latex sensitization among health care workers by using various methods, but the findings have been inconsistent and do not predict reactivity. This study used workers' compensation data from Minnesota from 1988 to 1997 to assess allergic reactivity rates, injury severity, and costs associated with latex allergic reactions. The average reactivity rate was 7.1 claims per 100,000 health care workers, and total cost associated with the claims averaged $0.295 per health care employee. Using empirical cost data from another study, it was found that it is not cost-beneficial for health care institutions to globally adopt latex glove-free policies solely on the basis of workers' compensation costs.

Entities:  

Mesh:

Year:  2000        PMID: 10998770     DOI: 10.1097/00043764-200009000-00018

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  3 in total

1.  Have health conditions associated with latex increased since the issuance of universal precautions?

Authors:  Brian P McCall; Irwin B Horwitz; John D Kammeyer-Mueller
Journal:  Am J Public Health       Date:  2003-04       Impact factor: 9.308

2.  Outcome of occupational latex allergy--work ability and quality of life.

Authors:  Albert Nienhaus; Kathrin Kromark; Monika Raulf-Heimsoth; Vera van Kampen; Rolf Merget
Journal:  PLoS One       Date:  2008-10-21       Impact factor: 3.240

3.  Workers' compensation claims related to natural rubber latex gloves among Oregon healthcare employees from 1987-1998.

Authors:  Irwin B Horwitz; John Kammeyer-Mueller; Brian P McCall
Journal:  BMC Public Health       Date:  2002-09-18       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.